These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33563803)

  • 1. Clinical spectrum of high-titre GAD65 antibodies.
    Budhram A; Sechi E; Flanagan EP; Dubey D; Zekeridou A; Shah SS; Gadoth A; Naddaf E; McKeon A; Pittock SJ; Zalewski NL
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(6):645-54. PubMed ID: 33563803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: Clinical spectrum and prognosis of a cohort from China.
    Bai L; Ren H; Liang M; Lu Q; Lin N; Liu M; Fan S; Cui R; Guan H
    Front Neurol; 2022; 13():990553. PubMed ID: 36277926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction.
    Pittock SJ; Yoshikawa H; Ahlskog JE; Tisch SH; Benarroch EE; Kryzer TJ; Lennon VA
    Mayo Clin Proc; 2006 Sep; 81(9):1207-14. PubMed ID: 16970217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder.
    Martinez-Hernandez E; Ariño H; McKeon A; Iizuka T; Titulaer MJ; Simabukuro MM; Lancaster E; Petit-Pedrol M; Planagumà J; Blanco Y; Harvey RJ; Saiz A; Graus F; Dalmau J
    JAMA Neurol; 2016 Jun; 73(6):714-20. PubMed ID: 27065452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
    Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
    JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.
    Muñoz-Lopetegi A; de Bruijn MAAM; Boukhrissi S; Bastiaansen AEM; Nagtzaam MMP; Hulsenboom ESP; Boon AJW; Neuteboom RF; de Vries JM; Sillevis Smitt PAE; Schreurs MWJ; Titulaer MJ
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAD65 neurological autoimmunity.
    McKeon A; Tracy JA
    Muscle Nerve; 2017 Jul; 56(1):15-27. PubMed ID: 28063151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in a case of low titre GAD65 antibody-associated spectrum neurological disorders.
    Wei M; Bannout F; Dastjerdi M; Phan C; Batarseh S; Guo X; Baker N
    BMJ Case Rep; 2024 Jun; 17(6):. PubMed ID: 38871638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
    Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
    JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pediatric autoimmune encephalitis associated with anti-glutamic acid decarboxylase 65 antibody: two cases report and literature review].
    Ren CH; Ren HT; Ren XT; Zhang WH; Li JW; Dai LF; Chen CH; Guan HZ; Fang F
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):47-52. PubMed ID: 33397004
    [No Abstract]   [Full Text] [Related]  

  • 11. Case Report: Autoimmune Encephalitis Associated With Anti-glutamic Acid Decarboxylase Antibodies: A Pediatric Case Series.
    Ren C; Ren H; Ren X; Zhang W; Li J; Dai L; Guan H; Fang F
    Front Neurol; 2021; 12():641024. PubMed ID: 33912125
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders.
    Chengyu L; Weixiong S; Chao C; Songyan L; Lin S; Zhong Z; Hua P; Fan J; Na C; Tao C; Jianwei W; Haitao R; Hongzhi G; Xiaoqiu S
    J Neuroimmunol; 2020 Aug; 345():577289. PubMed ID: 32563127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study.
    Muñiz-Castrillo S; Vogrig A; Montagnac C; Joubert B; Benaiteau M; Casez O; Chaumont H; Hopes L; Lanoiselée HM; Navarro V; Thomas B; Ursu R; Gonçalves D; Fabien N; Ducray F; Julier C; Honnorat J
    J Neurol; 2021 Jul; 268(7):2515-2522. PubMed ID: 33544221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria.
    Chia NH; McKeon A; Dalakas MC; Flanagan EP; Bower JH; Klassen BT; Dubey D; Zalewski NL; Duffy D; Pittock SJ; Zekeridou A
    Ann Clin Transl Neurol; 2023 Jul; 10(7):1083-1094. PubMed ID: 37212351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey.
    Matsui N; Tanaka K; Ishida M; Yamamoto Y; Matsubara Y; Saika R; Iizuka T; Nakamura K; Kuriyama N; Matsui M; Arisawa K; Nakamura Y; Kaji R; Kuwabara S; Izumi Y;
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37739810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stiff-man syndrome and variants: clinical course, treatments, and outcomes.
    McKeon A; Robinson MT; McEvoy KM; Matsumoto JY; Lennon VA; Ahlskog JE; Pittock SJ
    Arch Neurol; 2012 Feb; 69(2):230-8. PubMed ID: 22332190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation.
    Maniscalco GT; Zekeridou A; Allegorico L; Ranieri A; Napolitano M; Pezzella M; Gatta LD; Manzo V; Ferrari S; Mariotto S
    Neurol Sci; 2021 Oct; 42(10):4289-4291. PubMed ID: 33977307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs.
    Mäkelä KM; Hietaharju A; Brander A; Peltola J
    Front Neurol; 2018; 9():579. PubMed ID: 30057567
    [No Abstract]   [Full Text] [Related]  

  • 20. Meningoencephalitis associated with GAD65 autoimmunity.
    Kuang Z; Baizabal-Carvallo JF; Mofatteh M; Xie S; Pan M; Ye J; Zhou L; Yang S; Wang Z; Chen Y; Li Y
    Front Immunol; 2023; 14():1120894. PubMed ID: 36969186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.